Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lupus Nephritis: early-phase trial registry
15 of 31 indexed Lupus Nephritis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 15 currently recruiting · #495 of 28,707 conditions by registered trial count
Lupus Nephritis: 31 US clinical trials tracked, 15 recruiting.
Lupus Nephritis is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition lupus-nephritis
OPEN 15 | RECR 48% | LATE 6 | EARLY 21 | RANK #495 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Genetic Disease (48% recruiting · 31 trials)
Lupus Nephritis lists 15 open slots (48% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lupus Nephritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lupus Nephritis is recruiting above its size-band peers.
15 of 31 indexed trials (48.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lupus Nephritis trials is spread across many organizations.
Novartis Pharmaceuticals accounts for 3 of 31 trials (9.7%). 28 distinct sponsors appear on at least one study for this condition label.
-
Typical Lupus Nephritis enrolment sits around 80 participants.
Median target enrolment is 80 among the 31 trials that report a genuine target (sentinel values excluded). 18 of those (58.1%) plan for fewer than 100 participants.
-
Lupus Nephritis research is mostly interventional.
28 interventional and 3 observational studies make up this index (90.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
Lupus Landmark Study: A Prospective Registry and Biorepository
Lupus Research Alliance
NCT05934149
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
The Rogosin Institute
NCT01802034
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Novartis Pharmaceuticals
NCT05126277
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
GlaxoSmithKline
NCT06527872
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Novartis Pharmaceuticals
NCT05268289
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Novartis Pharmaceuticals
NCT06581198
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Children's Hospital Medical Center, Cincinnati
NCT05538208
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Nkarta
NCT06557265
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT07015983
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CRISPR Therapeutics
NCT06925542
VIBRANT: VIB4920 for Active Lupus Nephritis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05201469
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
M.D. Anderson Cancer Center
NCT06434363
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
NCT05039619
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
NephroNet
NCT07225387
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Cabaletta Bio
NCT06121297
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
AstraZeneca
NCT05138133
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
Hoffmann-La Roche
NCT04221477
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Alpine Immune Sciences
NCT05732402
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
Synthekine
NCT06544330
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
HI-Bio, A Biogen Company
NCT06064929
Daratumumab to Treat Active Lupus Nephritis
Mayo Clinic
NCT04868838
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
Kyverna Therapeutics
NCT05938725
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Century Therapeutics
NCT06255028
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Human Genome Sciences Inc., a GSK Company
NCT01639339
Aurinia Renal Response in Active Lupus With Voclosporin
Aurinia Pharmaceuticals
NCT03021499
Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients
Qure Healthcare
NCT04266860
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Boehringer Ingelheim
NCT02770170
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
Kezar Life Sciences
NCT03393013
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
Teva Branded Pharmaceutical Products R&D
NCT01085097
Phase Ib Study of SC Milatuzumab in SLE
Gilead Sciences
NCT01845740
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Apellis Pharmaceuticals
NCT03453619
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 10 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lupus Nephritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lupus Nephritis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lupus Nephritis page
31 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Lupus Nephritis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Lupus Nephritis trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lupus Nephritis condition card totals 31 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.